

**Appendix Table. Costs, population health effects and cost-effectiveness for 101 interventions in Mexico, by disease cluster.**

Intervention	Annual costs (I\$, millions)	Base-case analysis (DALYs with 3% discounting and age weights)			Sensitivity analysis (DALYs with 3% discounting and no age weighting)		
		Annual DALYs averted (thousands)	Average CE ratio	Incre-mental CE ratio	Annual DALYs averted (thousands)	Average CE ratio	Incre-mental CE ratio
<b>Depression</b>							
Combination of interventions at current coverage (20%)	136	43	3,189	Dominated	32	4,203	Dominated
Older anti-depressants in primary care at target coverage (50%)	319	121	2,630	Dominated	92	3,465	Dominated
Brief psychotherapy in primary care at target coverage (50%)	791	142	5,587	Dominated	107	7,373	Dominated
Older anti-depressant + psychotherapy at target coverage (50%)	844	146	5,768	Dominated	111	7,601	Dominated
Newer anti-depressant + psychotherapy at target coverage (50%)	780	163	4,789	Dominated	124	6,310	Dominated
Newer anti-depressant drug in primary care at target coverage (50%)	246	167	1,476	1,476	127	1,945	1,945
Older anti-depressant + psychotherapy + proactive case management at target coverage (50%)	701	255	2,745	Dominated	194	3,607	Dominated
Newer anti-depressant + psychotherapy + proactive case management at target coverage (50%)	586	268	2,184	3,354	204	2,870	4,386
<b>Heavy alcohol use</b>							
Roadside breath-testing (including non-fatal injuries)	133	23	5,855	Dominated	20	6,705	Dominated
Reduced access to retail outlets	11	38	283	Dominated	30	351	Dominated
Comprehensive advertising ban	14	43	318	Dominated	35	396	Dominated
Brief advice in primary care	128	45	2,842	Dominated	36	3,507	Dominated
Current taxation	13	146	90	Dominated	118	113	Dominated
Current scenario (tax and RBT at current	57	153	376	Dominated	123	466	Dominated

rates)							
Increased taxation (Current + 25%)	13	167	79	Dominated	135	98	Dominated
Increased taxation (Current + 50%)	13	184	72	72	148	89	89
Combination 1: Increased tax and scaled-up RBT	139	203	684	Dominated	164	843	Dominated
Combination 2: Increased tax and advertising ban	26	223	115	321	179	143	399
Combination 3: Increased tax and brief advice	138	225	613	Dominated	181	762	Dominated
Combination 4: Increased tax + ad ban + brief advice	147	264	556	Dominated	212	691	Dominated
Combination 5: Increased tax + brief advice + ad ban + reduced access	157	294	533	1,834	237	663	2,267
Combination 6: Increased tax + brief advice + ad ban + reduced access + scaled-up RBT	283	306	925	10,913	248	1,143	11,754
<b>Tobacco</b>							
Clean indoor air laws	24	3.7	6,611	Dominated	4.7	5,196	Dominated
Nicotine replacement therapy	163	4.1	39,443	Dominated	5.3	30,893	Dominated
Comprehensive advertising ban	14	6.8	2,028	Dominated	8.6	1,588	Dominated
Current scenario (tax at current rates)	13	35	377	Dominated	49	272	Dominated
Increased taxation	13	97	137	137	128	103	103
Combination 2: Tax increase + clean indoor air	37	98	376	Dominated	130	284	Dominated
Combination 1: Tax increase + ad ban	26	101	261	2,806	134	197	2,232
Combination 3: Tax increase + ad ban + clean indoor air	49	102	480	Dominated	134	364	Dominated
Combination 4: Tax increase + ad ban + clean indoor air + NRT	204	106	1,930	40,889	139	1,464	32,950
<b>Cataracts</b>							
ECCE-PC-IOL (hospital, 50%)	0.7	15	43	Dominated	20	33	Dominated
Phaco-PC-IOL (hospital, 50%)	0.7	16	42	42	21	33	33

ECCE-PC-IOL (hospital, 80%)	1.0	23	43	Dominated	29	33	Dominated
Phaco-PC-IOL (hospital, 80%)	1.0	24	42	42	31	33	33
ECCE-PC-IOL (hospital, 95%)	1.1	26	43	Dominated	33	33	Dominated
Phaco-PC-IOL (hospital, 95%)	1.2	27	42	43	35	33	34
<b>Breast cancer</b>							
Treatment at all stages	17	11	1,600	1,825	12	1,411	1,627
Stage I treatment	3.2	3.0	1,045		3.5	898	
Stage II treatment	12	7.1	1,680		8.1	1,486	
Stage III treatment	6.2	1.3	4,858		1.4	4,526	
Stage IV treatment	1.2	0.1	8,318		0.1	8,271	
Treatment at all stages plus screening	341	25	13,466	21,983	30	11,501	18,358
<b>Cervical cancer</b>							
Treatment at all stages	24	5.6	4,361	5,306	6.8	3,579	Dominated
CIN 2/3 treatment	5.0	1.9	2,587		2.6	1,954	
Local treatment	15	3.1	4,749		3.7	3,970	
Regional treatment	6.1	0.6	10,928		0.5	11,190	
Distant treatment	0.4	0.1	5,516		0.1	5,962	
Treatment at all stages plus screening	346	63	5,478	5,586	82	4,223	4,297
<b>Chronic obstructive pulmonary disease</b>							
Treatment of severe exacerbations	33	0.3	103,671	Dominated	0.4	76,819	Dominated
Oxygen therapy in addition to medication for severe disease (stage IV)	60	1.0	58,395	Dominated	1.6	38,123	Dominated
Inhaled bronchodilator (stage II)	308	1.7	180,520	Dominated	1.8	169,652	Dominated
Inhaled bronchodilator and corticosteroid (stage III and IV)	70	3.2	22,034	Dominated	4.3	16,337	Dominated
Influenza vaccine	10	3.8	2,758	2,758	6.6	1,585	1,585
Smoking cessation	33	6.4	5,059	8,367	7.9	4,140	17,563
<b>Cardiovascular disease, primary prevention</b>							

Population salt reduction, by 15%	11	19	570	Dominated	27	408	Dominated
Population salt reduction, by 30%	11	37	293	293	52	210	210
Population cholesterol	22	38	567	Dominated	48	458	Dominated
Individual cholesterol, >240mg/dL	1,369	167	8,174	Dominated	206	6,638	Dominated
Absolute risk, 35% threshold	103	169	612	703	228	453	526
Individual hypertension, >160mmHg	163	187	875	Dominated	258	632	1,985
Individual cholesterol, >220mg/dL	2,115	197	10,714	Dominated	247	8,562	Dominated
Absolute risk, 25% threshold	212	204	1,039	Dominated	282	753	2,082
Individual hypertension, >140mmHg	990	257	3,855	Dominated	353	2,807	Dominated
Absolute risk, 15% threshold	531	261	2,034	Dominated	369	1,439	Dominated
Population combination	654	348	1,879	3,076	465	1,405	2,408
Absolute risk, 5% threshold	1,481	358	4,140	84,232	505	2,934	20,927
<b>Cardiovascular disease, treatment and secondary prevention</b>							
Aspirin (acute ischemic stroke)	97	0.8	120,526	Dominated	1.0	96,772	Dominated
Beta blocker (acute MI)	33	1.6	20,309	Dominated	2.1	15,884	Dominated
ACE inhibitor (acute MI)	33	2.8	11,607	Dominated	3.6	9,078	Dominated
Organised stroke unit care	122	4.3	28,250	Dominated	5.1	23,682	Dominated
ACE inhibitor (CHF)	5.9	5.3	1,100	Dominated	6.2	946	Dominated
Aspirin (post-acute IHD)	19	6	2,975	Dominated	10	1,920	Dominated
Aspirin (acute MI)	33	10	3,388	Dominated	12	2,650	Dominated
Thrombolysis with streptokinase	75	10	7,138	Dominated	13	5,582	Dominated
Beta blocker (CHF)	4.8	11	445	Dominated	13	383	Dominated
Statin (post-acute IHD)	86	11	7,864	Dominated	17	5,109	Dominated
Exercise training (CHF)	7.0	18	402	Dominated	20	346	Dominated
Aspirin (acute MI) + STK	75	18	4,243	Dominated	22	3,318	Dominated
Aspirin + beta blocker + ACE inhibitor + STK (acute MI)	76	20	3,772	Dominated	26	2,949	Dominated
Beta blocker (post-acute IHD)	24	21	1,117	Dominated	28	835	Dominated

ACE inhibitor (post-acute IHD)	24	23	1,045	Dominated	30	799	Dominated
Primary PTCA	83	24	3,416	Dominated	31	2,671	Dominated
Aspirin (post acute ischemic stroke)	29	25	1,164	Dominated	35	830	Dominated
Beta blocker (post-acute IHD) + aspirin (post-acute IHD)	24	27	887	Dominated	37	640	Dominated
Cardiac rehabilitation	1.4	27	50	50	35	38	38
Aspirin (acute MI) + PTCA	84	28	2,972	Dominated	36	2,324	Dominated
Aspirin (acute MI) + beta blocker (acute MI) + ACE inhibitor (acute MI) + PTCA	84	30	2,846	Dominated	38	2,225	Dominated
Beta blocker (post-acute IHD) + aspirin (post-acute IHD) + statin (post-acute IHD)	101	35	2,884	Dominated	50	2,020	Dominated
Diuretic (CHF)	7.7	40	194	500	46	167	590
Statin (post-acute ischemic stroke)	79	45	1,762	Dominated	63	1,263	Dominated
ACE inhibitor + diuretic (post Stroke)	58	47	1,226	Dominated	67	873	Dominated
All heart failure interventions	18	48	383	1,301	56	330	1,120
All secondary pharmacologic prevention (AMI)	111	52	2,116	Dominated	73	1,525	Dominated
Statin for stroke and MI	165	56	2,938	Dominated	80	2,065	Dominated
Aspirin + beta blocker + statin for MI & Stroke (secondary prevention)	233	101	2,303	Dominated	143	1,629	Dominated
All secondary prevention (Stroke)	117	101	1,158	1,849	144	816	1,122
<b>Diabetes</b>							
Lipid control	147	8.5	17,311	Dominated	8.2	17,860	Dominated
Blood pressure control	140	16	8,562	8,562	17	8,512	8,512
Conventional glycemic control	423	34	12,496	16,191	33	12,748	16,934
Intensive glycemic control	623	46	13,632	16,889	45	13,867	17,042